667 results about "Artemisinin" patented technology

Compositions and methods for treating patients suffering from a proliferation disorder characterized by an increased voltage gated ion-channel uptake are described. Included are compositions comprised of a compound selected from the group consisting of matrine, oxymatrine, artemisinin, agmatine, and vinpocetine.

The present invention relates to methods for the conversion of amorpha-4,11-diene to artemisinin and various artemisinin precursors.

The invention relates to a preparation method of a bionic artemisinin molecular imprinting composite membrane, belonging to the technical field of environmental material preparation. The preparation method comprises the following specific steps: by taking a regenerated cellulose membrane as a substrate, artemisinin as a template molecule, acrylamide (AM) as a functional monomer and ethylene glycol dimethacrylate (EGDMA) as a cross-linking agent, inlaying silicon dioxide nanoparticles with functional monomer modified surfaces to the surface of a membrane material by combination with a dopamine bionic principle, and performing two-step temperature polymerization to prepare the bionic artemisinin molecular imprinting composite membrane. The static adsorption experiment is used for making a research on the adsorption balance, dynamics and selective recognition performance of the prepared imprinting membrane. A result shows that the artemisinin imprinting membrane prepared by adopting the method is relatively high in adsorption capacity and superior in artemisinin molecular recognition penetration performance.

The present invention provides artemisinic epoxide, and methods of synthesizing artemisinic epoxide in a genetically modified host cell. The present invention further provides methods for producing artemisinin. The present invention further provides variant enzymes that catalyze the oxidation of amorpha-4,11-diene to artemisinic epoxide; nucleic acids encoding the variant enzymes; as well as recombinant vectors and host cells comprising the nucleic acids.

The invention provides a plant allergy-relieving agent and a preparation method thereof. The preparation method comprises the following steps: weighing raw materials according to proportions, and extracting in an extracting device so as to obtain an extracting solution A; filtering the extracting solution A, and reserving permeate liquid as an extracting solution B; and concentrating the extracting solution B so as to obtain a final product, namely the plant allergy-relieving agent. The plant allergy-relieving agent consists of the following raw materials in parts by weight: 20-30 parts of liquorice root, 20-30 parts of artemisia apiacea, 10-20 parts of radix gentianae, 10-20 parts of radix sophorae flavescentis and 10-20 parts of fructus cnidii. The cosmetic plant allergy-relieving agent, which is effective, stable and light in color, is prepared by virtue of a special process; and the prepared plant allergy-relieving agent consists of 0.25-0.35% of glycyrrhizic acid and 0.61-0.87mg/ml of artemisinin in percentage by mass.

The present invention is directed to a composition for the treatment of Lyme disease, comprising: Uncaria tomentosa (Cat's Claw); Pau d'arco; Scutellaria baicalensis (Baikal Scullcap); Artemisinin; and Sambucus nigra (Elderberry).

The invention relates to a coding sequence of an AaMYBL1 protein of artemisia apiacea and an application thereof. The amino acid sequence coded by the coding sequence AaMYBL1 of an MYB-like type transcription factor of artemisia apiacea is shown as SEQ ID NO:4. The AaMYBL1 which codes a R3MYB type transcription factor takes part in regulation of density of glandular hairs of artemisia apiacea. An interference vector of the AaMYBL1 transcription factor of artemisia apiacea is transformed into artemisia apiacea by means of the transgenic technology, so that the density of the glandular hairs on the surface of artemisia apiacea can be effectively regulated, thus, the content of artemisinin is improved. The density of the glandular hairs on the surface of a blade of non-transgenic common artemisia apiacea is 24/square millimeter, and the density of the glandular hairs of a blade of transgenic artemisia apiacea inhibiting AaMYBL1 genetic expression is increased to 34/square millimeter; the quantity of total glandular hairs of each blade is increased from 61947 to 93683; correspondingly, the content of artemisinin is improved from 8mg/g DW of non-transgenic artemisia apiacea to 12mg/g DW. The coding sequence provided by the invention is of significance for providing a high-yield stable novel medicine source for scaled production of artemisinin.

The present invention relates to a method for converting amorpha-4,11-diene into artemisinin and various artemisinin precursors.

The invention discloses a superparamagnetic ferroferric oxide nano particle drug carrier. The rug carrier comprises superparamagnetic ferroferric oxide nano particles which are formed by polymerizing ferroferric oxide nanocrystal with the size being smaller than 10nm and can release ferrous ion under an acidic condition, an amorphous carbon layer which is coated on the surface of the superparamagnetic ferroferric oxide nano particles and can be resolved in an alkaline condition, silver nano particles coated on the surface of the carbon layer, and a silicon dioxide layer, with a porous structure, coated on the surface of the silver nano particle. The drug carrier can load natural drug artemisinin, overcome the disadvantage of poor water solubility of artemisinin, and convey more artemisinin to a tumor focus part through intravenous injection, after the artemisinin reaches the tumor part, as tumor cell is in acid microenvironment, the drug carrier releases ferrous ion in the cell, the ferrous ion cracks peroxide bridges in the tumor, free radical is produced, protein, DNA (deoxyribonucleic acid) and cell membrane of the tumor cell are destroyed, finally the tumor cell is killed, and the anti-tumor efficacy of artemisinin is improved.

A new formulation and process of producing a new formulation of artemisinin in the form of a complexation of artemisinin with beta-cyclodextrins. This new formulation of artemisinin having greater aqueous solubility, a higher dissolution rate and an improved bioavailability.

The invention provides an application of arteannuim and a derivative thereof in preparing a chemotherapeutic synergist. The chemotherapeutic synergist and a chemotherapeutic agent are used together to cure tumors.

This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition.

The invention discloses anti-dandruff shampoo with an effect of improving the microbial flora on the scalp skin. The anti-dandruff shampoo is prepared from the following raw materials: water, polydimethylsiloxane, glycol stearate, sodium lauroyl sarcosine, polyquaternium-10, cetostearyl alcohol, ammonium chloride, vaccinium uliginosum berry extract, celery seed extract, silk hydrolysate, zinc pyrithione, piroctone olamine, EDTA disodium, surfactant, preservatie, artemisinin and rosemary water. The invention further discloses a preparation process of the shampoo. The shampoo can be used for improving the microbial environment of the scalp skin and improving the resistance of the scalp skin and can achieve the effect of effectively removing dandruff and preventing dandruff reoccurrence.

A method for extracting arteannuic acid from artemisinin crystallization mother liquor comprises the following steps of (1) saponification; (2) acidification: (3) extraction; (4) dry column chromatography; and (5) purification. By means of the method, high-content arteannuic acid can be effectively separated and purified from the artemisinin crystallization mother liquor, so that the crystallization mother liquor of no use at all at former days is changed to be valuable, waste of resources is reduced, and comprehensive development and utilization of artemisia apiacea resources are promoted.

The present invention discloses the new use of available antimalarial arteannuin and its derivatives dihydro arteannuin, antiannuic methyl ether, antiannuic ethyl ether and antiannuic amber. Arteannuin and its derivatives are used through combination with antibiotic medicine to inhibit bacterial growth and enhance the antibiotic effect of available antibiotic medicine. Especially, antiannuic amber is applied in preventing and treating bacterial infection diseases except being used as antimalarial.

The invention relates to an artemisinin molecule imprinting polymer on the surface of porous microsphere silica gel. The artemisinin molecule imprinting polymer is prepared by adopting the steps of: selecting the porous microsphere silica gel as a basal material, taking vinyl triethoxysilane as a coupling agent, artemisinin as a template molecule, methacrylate and acrylamide as functional monomers, ethylene glycol dimethacrylate as a cross-linking agent and azodiisobutyronitrile as an initiating agent, preparing a polymer and removing the artemisinin in the polymer. The invention also provides a preparation method and an application method of the artemisinin molecule imprinting polymer on the surface of the porous microsphere silica gel. The artemisinin molecule imprinting polymer on the surface of the porous microsphere silica gel can separate the artemisinin from other structural analogues, such as artemether, and the like under normal pressure and temperature and supercritical conditions, is especially suitable for supercritical conditions and has specific adsorption property, selectivity and favorable mechanical stability; and the preparation method is simple, convenient and suitable for large-scale popularization and application.

The invention discloses a preparation method and application of a porous core-shell double-metal organic framework nano drug carrier. The porous core-shell double-metal organic framework nano drug carrier takes a Prussian blue porous metal organic framework nano particle as a core, and an iron-containing porous metal organic framework MIL-100 covers the surface of a Prussian blue porous metal organic framework. The drug carrier disclosed by the invention can be used for carrying a natural drug artemisinin and the disadvantage that the water solubility of the artemisinin is poor is overcome; more artemisinin is delivered to tumor focus positions through intravenous infusion; after the artemisinin reaches the tumor positions, tumor cells are located in an acidic microenvironment, so that the iron-containing porous metal organic framework on the outer layer can be degraded and the carried artemisinin is released; meanwhile, under the irradiation of 808nm laser, the core Prussian blue nano particle can generate partial high heat for directly killing the tumor cells; finally, the synergistic anticancer effect combining artemisinin chemical therapy and Prussian blue photo-thermal therapy is realized.

The present invention relates to an isolated DNA sequence encoding a polypeptide having the biological activity of amorpha-4,11-diene synthase. This DNA sequence can be used for the transformation of bacteria, yeasts and plants for the production of amorpha-4,11-diene, a specific precursor in the synthesis of artemisinin, in the respective organisms. The invention also relates to these organisms.

The invention relates to a simple process for extracting artemisinin from artemisa apiacea. The process comprises: placing dried artemisa apiacea leaf in a 3-mouthed bottle as a raw material, adding a solvent/water mixing system, soaking for 1-2 h, carrying out ultrasonic assisted extraction for 2-4 h, and repeating the extraction two times, wherein the third extraction solution is mechanically applied, the mixed extraction solution is used for the next separation and purification processes, and high-performance liquid chromatography detection results show that an extraction recovery rate is more than 98%. The method has characteristics of simple process and simple operation.

The invention relates to the technical field of mosquito repellent products, in particular to plant mosquito repellent based on artemisia annuae oil. The artemisia annuae oil of the plant mosquito repellent serves as the effective constituent, the artemisia annuae oil is a remaining residue obtained when artemisinin is extracted from artemisia annuae, and the content of the artemisinin is lower than 1%. According to the plant mosquito repellent, the artemisia annuae oil which is the remaining residue obtained when the artemisinin is extracted from the artemisia annuae is sufficiently developed and utilized, and the plant mosquito repellent has the good mosquito repellent effect.

The invention relates to a method for preparing a veterinary oxytetracycline-artemisinin injection and clinical application of the veterinary oxytetracycline-artemisinin injection. Raw materials of the injection mainly comprise oxytetracycline, artemisinin, trimethoprim, flunixin meglumine, magnesium oxide or magnesium chloride, an antioxidant, a pH regulator, a compound organic solvent and water. As a veterinary compound preparation, the veterinary oxytetracycline-artemisinin injection is mainly used for treating infectious diseases and secondary infection which are caused by sensitive gram positive bacteria and negative bacteria, eperythrozoon, rickettsia and mycoplasma. The method for preparing the veterinary compound oxytetracycline-artemisinin injection is simple, the production process is mild, the chelating temperature is low, the stability is high, and the injection is convenient to use and is suitable for industrialized production.

The invention discloses a berberine. artemisinin composite algicide which mainly contains 600mg/L of berberine and 6-7.5mg/L of artemisinin. The algicide provided by the invention is used for controlling cyanobacterial bloom, when the net content of berberine reaches 10.0mg/L and the net content of artemisinin is more than 0.1mg/L in the pond water, the cyanobacteria amount in the water drops to the 10% of the initial density value after 10 days. The algicide provided by the invention is mainly applied to the prevention and control of harmful cyanobacterial bloom in artificial water systems, lakes, reservoirs, ponds and other freshwater bodies. The composite algicide provided by invention is botanical algicide, and has strong and durable inhibitory effect on algae, no significant impact on other aquatic organisms and no environmental pollution.

The invention discloses a surface artemisinin molecule imprinting adsorbing material of a vegetable sponge. The material is characterized characterized by being prepared by the following steps of: preparing a polymer by selecting vegetable sponge as a substrate material, taking artemisinin as a template molecule, taking itaconic acid and acrylamide as functional monomers, taking ethylene glycol dimethacrylate as a cross-linking agent, taking azodiisobutyronitrile as an initiator and taking N,N-dimethylformamide as a solvent; and removing the artemisinin by using a hexane-diethyl ether mixed solution. The invention further provides a preparation method and an application method of the surface artemisinin molecule imprinting adsorbing material of the vegetable sponge. The surface artemisinin molecule imprinting adsorbing material of the vegetable sponge can separate the artemisinin with a structural analogue under normal pressure and temperature conditions; and the surface artemisinin molecule molecular imprinting adsorbing material of the vegetable sponge has the advantages of specificity, selectivity, good mechanical performance, good chemical stability, fast adsorbing speed, easiness for being eluted, biodegradability, simple process, regeneration capability, environmental friendliness and the like.